Investors
Adjuvant Capital
Adjuvant Capital is a venture capital fund specializing in early to mid-stage companies in biotech, health tech, and manufacturing. They invest $10 million to $25 million in firms addressing significant health challenges. Notable investments include Memo Therapeutics, Univercells, and LimmaTech Biologics. Adjuvant Capital aims to make a global impact by supporting solutions for high-burden and neglected diseases.
Recent Investments
- LimmaTech BiologicsSeries A( 33 )
- Memo TherapeuticsSeries C( 37 )
- UnivercellsSeries C( 48 )